# DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

> **NCT06176261** · PHASE2 · RECRUITING · sponsor: **Sarah Sammons, MD** · enrollment: 58 (estimated)

## Conditions studied

- Breast Cancer
- Breast Cancer Female
- Metastatic Triple-Negative Breast Carcinoma
- ER Positive Breast Cancer
- HER2-negative Breast Cancer
- HER2 Negative Breast Carcinoma
- ER-negative Breast Cancer

## Interventions

- **DRUG:** Datopotamab Deruxtecan

## Key facts

- **NCT ID:** NCT06176261
- **Lead sponsor:** Sarah Sammons, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-08
- **Primary completion:** 2028-01-01
- **Final completion:** 2029-01-01
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2025-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06176261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06176261, "DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06176261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*